Deutsche Bank AG Has $1.91 Million Stake in Phreesia, Inc. $PHR

Key Points

• Deutsche Bank AG increased its stake in Phreesia, Inc. by 30.6% during the first quarter, now owning 74,857 shares worth approximately $1.91 million.
• Phreesia's stock price rose 3.6%, with a current trading value of $28.70 and a market cap of $1.71 billion.
• The company reported quarterly earnings of ($0.07) EPS, exceeding analysts' expectations and showing a 14.5% increase in revenue compared to the same quarter last year.

Deutsche Bank AG grew its holdings in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 30.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,857 shares of the company's stock after purchasing an additional 17,560 shares during the quarter. Deutsche Bank AG owned about 0.13% of Phreesia worth $1,913,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Johnson Financial Group Inc. raised its holdings in Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after acquiring an additional 896 shares during the period. Quarry LP raised its holdings in Phreesia by 210.9% in the 4th quarter. Quarry LP now owns 2,835 shares of the company's stock worth $71,000 after acquiring an additional 1,923 shares during the period. KBC Group NV bought a new position in Phreesia in the 1st quarter worth $74,000. CWM LLC raised its holdings in Phreesia by 994.9% in the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after acquiring an additional 3,671 shares during the period. Finally, NewEdge Advisors LLC raised its holdings in Phreesia by 12.1% in the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after acquiring an additional 459 shares during the period. Institutional investors own 92.10% of the company's stock.

Insider Activity

In other Phreesia news, Director Lisa Egbuonu-Davis sold 2,802 shares of the business's stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $27.67, for a total transaction of $77,531.34. Following the completion of the sale, the director directly owned 22,037 shares of the company's stock, valued at approximately $609,763.79. The trade was a 11.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Evan Roberts sold 1,892 shares of the business's stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $26.89, for a total value of $50,875.88. Following the sale, the chief operating officer directly owned 772,915 shares of the company's stock, valued at $20,783,684.35. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 53,882 shares of company stock worth $1,513,007. Corporate insiders own 5.50% of the company's stock.

Phreesia Price Performance

Shares of NYSE:PHR traded up $0.61 on Monday, hitting $30.36. The stock had a trading volume of 1,047,812 shares, compared to its average volume of 523,506. The firm's 50 day moving average price is $27.49 and its 200-day moving average price is $26.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $31.04. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.03 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last posted its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $115.94 million for the quarter, compared to analyst estimates of $115.00 million. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The firm's quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.05) EPS. Phreesia has set its FY 2026 guidance at EPS. On average, equities research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

PHR has been the subject of a number of research reports. Citigroup reissued a "buy" rating on shares of Phreesia in a report on Wednesday, May 28th. KeyCorp increased their price target on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a report on Monday, July 14th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Canaccord Genuity Group reduced their price target on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. Finally, Truist Financial increased their price target on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company's stock. According to MarketBeat, Phreesia currently has an average rating of "Buy" and a consensus target price of $32.27.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.